Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.34 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16695529 | 1.00 | LOX (0.49) | LOXLOXL2HCRTR1HCRTR2AVPR1A | |
| SCHEMBL20266990 | 0.93 | LOX (0.54) | LOXLOXL2HCRTR1HCRTR2AVPR1A | |
| SCHEMBL18159813 | 0.92 | HCRTR1 (0.44) | LOXLOXL2HCRTR1HCRTR2AVPR1A | |
| SCHEMBL18150702 | 0.92 | HCRTR1 (0.44) | LOXLOXL2HCRTR1HCRTR2AVPR1A | |
| SCHEMBL17448838 | 0.92 | HCRTR1 (0.47) | LOXLOXL2HCRTR1HCRTR2AVPR1A | |
| SCHEMBL18150701 | 0.92 | HCRTR1 (0.44) | LOXLOXL2HCRTR1HCRTR2AVPR1A | |
| SCHEMBL30001347 | 0.91 | LOX (0.60) | LOXLOXL2HCRTR1HCRTR2AVPR1A | |
| SCHEMBL25323010 | 0.89 | HCRTR1 (0.43) | LOXLOXL2HCRTR1HCRTR2AVPR1A | |
| SCHEMBL18150931 | 0.88 | HCRTR1 (0.44) | LOXLOXL2HCRTR1HCRTR2AVPR1A | |
| SCHEMBL3323298 | 0.88 | HDAC6 (0.50) | LOXLOXL2HCRTR1HCRTR2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| CN-115461120-A | Sulfonylimide compounds as NLRP3 modulators | 豪夫迈·罗氏有限公司 | 2022-12-09 | — | — | CN | disclosed |
| EP-4058016-A1 | THIOPHENE COMPOUNDS WITH CYCLIC AMIDES, AND USES THEREOF | Capulus Therapeutics, LLC (US) | 2022-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | LOX 2148/4885LOXL2 3586/4885HCRTR1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.